CN113234142B - 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用 - Google Patents

超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用 Download PDF

Info

Publication number
CN113234142B
CN113234142B CN202110418890.8A CN202110418890A CN113234142B CN 113234142 B CN113234142 B CN 113234142B CN 202110418890 A CN202110418890 A CN 202110418890A CN 113234142 B CN113234142 B CN 113234142B
Authority
CN
China
Prior art keywords
ser
amino acid
leu
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110418890.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113234142A (zh
Inventor
李滢权
金圣根
朴荣燮
南效廷
金董植
朴在燦
尹桦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Institute for Biomedical Research
Original Assignee
Mogam Biotechnology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Biotechnology Research Institute filed Critical Mogam Biotechnology Research Institute
Priority to CN202110418890.8A priority Critical patent/CN113234142B/zh
Publication of CN113234142A publication Critical patent/CN113234142A/zh
Application granted granted Critical
Publication of CN113234142B publication Critical patent/CN113234142B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202110418890.8A 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用 Active CN113234142B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110418890.8A CN113234142B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110418890.8A CN113234142B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN201280076586.9A CN104769113B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
PCT/KR2012/006680 WO2014030780A1 (en) 2012-08-22 2012-08-22 Screening and engineering method of super-stable immunoglobulin variable domains and their uses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280076586.9A Division CN104769113B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用

Publications (2)

Publication Number Publication Date
CN113234142A CN113234142A (zh) 2021-08-10
CN113234142B true CN113234142B (zh) 2024-03-05

Family

ID=50150075

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110418890.8A Active CN113234142B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN201610833668.3A Active CN106986934B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN201280076586.9A Active CN104769113B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201610833668.3A Active CN106986934B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN201280076586.9A Active CN104769113B (zh) 2012-08-22 2012-08-22 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用

Country Status (6)

Country Link
US (1) US10078085B2 (https=)
EP (2) EP3165535B1 (https=)
JP (1) JP6073038B2 (https=)
KR (2) KR101796689B1 (https=)
CN (3) CN113234142B (https=)
WO (1) WO2014030780A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014030780A1 (en) * 2012-08-22 2014-02-27 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
GB201419899D0 (en) 2014-11-07 2014-12-24 Univ Kent Canterbury Biopharmaceutical production method
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
KR101692629B1 (ko) * 2015-07-14 2017-01-03 계명대학교 산학협력단 매시브 플래카드 제어 장치 및 그 방법
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
AU2017259821B2 (en) * 2016-05-04 2024-07-18 Abilita Bio, Inc. Methods and platform for preparing multispanning membrane proteins
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
CN111201243B (zh) 2017-09-29 2023-08-11 财团法人牧岩生命科学研究所 对bcma具有高亲和力的抗bcma抗体和包含其的用于治疗癌症的药物组合物
KR102115300B1 (ko) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
CN108893487A (zh) * 2018-07-19 2018-11-27 中国农业科学院北京畜牧兽医研究所 一种含有C-Myc蛋白融合标签的植物表达质粒载体及其载体的构建方法
WO2020127993A1 (en) * 2018-12-21 2020-06-25 Vib Vzw Fusion protein with a toxin and scaffold protein

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1662556A (zh) * 2002-05-22 2005-08-31 艾斯巴技术股份公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN1735630A (zh) * 2003-01-10 2006-02-15 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
CN104769113A (zh) * 2012-08-22 2015-07-08 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960007784B1 (ko) 1993-07-02 1996-06-12 포항종합제철 주식회사 일산화탄소(co)가스 센서 및 그 제조방법
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP2002531113A (ja) * 1998-12-10 2002-09-24 ワシントン大学 蛋白質の形質導入システムおよびその使用法
WO2001018058A2 (en) * 1999-09-07 2001-03-15 Viventia Biotech Inc. Enhanced phage display library of human vh fragments and methods for producing same
US8372954B2 (en) * 2000-12-22 2013-02-12 National Research Council Of Canada Phage display libraries of human VH fragments
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
WO2006026759A2 (en) 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
US20070026012A1 (en) * 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
EP2360473A1 (en) * 2005-08-22 2011-08-24 Cornell Research Foundation Compositions and methods for analyzing protein interactions
EP1981979A4 (en) 2006-01-31 2009-07-29 Republic Of Korea Republic Of PROCESS FOR PRODUCING A SOLUBLE NATIVE FORM OF RECOMBINANT PROTEIN USING THE SIGNAL SEQUENCE AND A SECRETION ENHANCING AGENT
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
CN101720368A (zh) * 2007-03-09 2010-06-02 中国抗体制药有限公司 储备多样性最大化的功能性人化抗体文库之构建及应用
KR20100024943A (ko) * 2007-06-18 2010-03-08 다니스코 유에스 인크. 원핵생물에서의 단백질 생성을 위한 ｔａｔ 신호 펩타이드
WO2009089295A2 (en) * 2008-01-07 2009-07-16 Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Anti-hiv domain antibodies and method of making and using same
JP6093715B2 (ja) 2011-01-28 2017-03-08 ナショナル リサーチ カウンシル オブ カナダ 免疫グロブリンドメインの工学的作製

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1662556A (zh) * 2002-05-22 2005-08-31 艾斯巴技术股份公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN1735630A (zh) * 2003-01-10 2006-02-15 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
CN104769113A (zh) * 2012-08-22 2015-07-08 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CN106986934A (zh) * 2012-08-22 2017-07-28 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Directed evolution of human heavy chain variable domain (VH) using in vivo protein fitness filter;Kim et al;PLOS ONE;第9卷(第6期);e98178 *
新型可溶性融合蛋白TAT-PEP对SD大鼠缺血性脑损伤的保护作用及相关机制研究;邓斌;中国博士学位论文全文数据库医药卫生科技辑(第02期);E066-14 *

Also Published As

Publication number Publication date
JP6073038B2 (ja) 2017-02-01
CN106986934A (zh) 2017-07-28
WO2014030780A1 (en) 2014-02-27
KR101796689B1 (ko) 2017-11-10
KR20150032337A (ko) 2015-03-25
CN104769113B (zh) 2017-10-31
US10078085B2 (en) 2018-09-18
KR20160072272A (ko) 2016-06-22
EP3165535A1 (en) 2017-05-10
CN106986934B (zh) 2021-09-14
JP2015531597A (ja) 2015-11-05
EP2888367B1 (en) 2020-04-29
EP3165535B1 (en) 2019-05-15
EP2888367A1 (en) 2015-07-01
KR101732552B1 (ko) 2017-05-08
CN104769113A (zh) 2015-07-08
EP2888367A4 (en) 2016-04-20
US20160003844A1 (en) 2016-01-07
CN113234142A (zh) 2021-08-10

Similar Documents

Publication Publication Date Title
CN113234142B (zh) 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
EP3288973B1 (en) Method for mass humanization of rabbit antibodies
JP2015531597A5 (https=)
US10415033B2 (en) Phage-displayed single-chain variable fragment libraries and uses thereof
CN107513104A (zh) 免疫球蛋白结构域的工程改造
CN115536747B (zh) 一种结合trop2的抗体及靶向trop2和cd3的双特异性抗体及其制备方法与应用
KR102216032B1 (ko) 합성 항체 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들)
HK40051447B (zh) 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
HK40051447A (en) Screening and engineering method of super-stable immunoglobulin variable domains and their uses
CN112424221B (zh) 抗体文库和使用抗体文库的抗体筛选方法
Rajput et al. Phage-display technology for the production of recombinant monoclonal antibodies
JP6293829B2 (ja) 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用
Bostrom et al. Design and construction of synthetic phage-displayed Fab libraries
Leow et al. Monoclonal IgY antibodies
Steven et al. In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties
WO2022120024A1 (en) Variable heavy chain only libraries, methods of preparation thereof, and uses thereof
HK40039219B (zh) 抗体文库和使用抗体文库的抗体筛选方法
Salema et al. Advances in Antibody Phage Display-A review
Keklikian Construction of a Synthetic Human VL Phage Display Library and Isolation of Potential Neuropilin-1-specific VL Therapeutics from the Library

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051447

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Seoul, South Kerean

Patentee after: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Country or region after: Republic of Korea

Address before: Gyeonggi Do, South Korea

Patentee before: MOGAM BIOTECHNOLOGY Research Institute

Country or region before: Republic of Korea

EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20210810

Assignee: GREEN CROSS Corp.

Assignor: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Contract record no.: X2025990000124

Denomination of invention: Screening and modification methods of ultra stable immunoglobulin variable domains and their applications

Granted publication date: 20240305

License type: Exclusive License

Record date: 20250327